Neratinib in patients with HER2+ breast cancer: a multi-centric, multi-national, prospective, longitudinal, non-interventional study in Switzerland, Germany and Austria. rEal-LifE pAN-HER-blOckade with neRatinib: ELEANOR

Cancer is a disease that happens when some of the body's cells start to grow uncontrollably. Breast cancer is one of the most frequently diagnosed cancer. Nerlynx® is registered in Europe. Nerlynx is used in people who have early stage breast cancer which is hormone receptor positive (HR-positive) and human epidermal growth factor receptor 2- positive (HER2) overexpressed/amplified (HER2 positive), and has previously been treated with trastuzumab based therapy that ended less than one year ago. Compliance to the treatment is a key factor. The compliance might have an impact on efficacy of the neratinib treatment. This study aimed to study the real-world use of neratinib in people with breast cancer.